Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression

Virology

Volumn 424, Issue 1, 2012, Pages 3-10

  Gnirß, Kerstin ^a   Kühl, Annika ^a   Karsten, Christina ^a,b   Glowacka, Ilona ^a   Bertram, Stephanie ^a,b   Kaup, Franziska ^b   Hofmann, Heike ^b   Pöhlmann, Stefan ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

Author keywords

Cathepsin; Ebola; Entry; Glycoprotein; Proteolytic activation

Indexed keywords

CATHEPSIN B; CATHEPSIN L; LEUPEPTIN; SERINE PROTEINASE; TYPE II TRANSMEMBRANE SERINE PROTEASE TMPRSS2; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DEMOCRATIC REPUBLIC CONGO; EBOLA VIRUS; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MACROPHAGE; MARBURG VIRUS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; VIRUS ACTIVATION; VIRUS ENTRY;

CATHEPSIN B; CATHEPSIN L; CELL LINE; EBOLAVIRUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACROPHAGES; MARBURGVIRUS; SERINE ENDOPEPTIDASES; VIRAL PROTEINS; VIRUS INTERNALIZATION;

LAKE VICTORIA MARBURGVIRUS; ZAIRE EBOLAVIRUS;

EID: 84856225495     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.11.031     Document Type: Article

References (49)

1. Aoyagi T., Takeuchi T., Matsuzaki A., Kawamura K., Kondo S. Leupeptins, new protease inhibitors from Actinomycetes. J. Antibiot. (Tokyo) 1969, 22:283-286.
2. Bertram S., Glowacka I., Blazejewska P., Soilleux E., Allen P., Danisch S., Steffen I., Choi S.Y., Park Y., Schneider H., Schughart K., Pöhlmann S. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 2010, 84:10016-10025.
3. Bertram S., Glowacka I., Steffen I., Kühl A., Pöhlmann S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev. Med. Virol. 2010, 20:298-310.
4. Böttcher E., Matrosovich T., Beyerle M., Klenk H.D., Garten W., Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006, 80:9896-9898.
5. Bush G., diSibio G., Miyamoto A., Denault J.B., Leduc R., Weinmaster G. Ligand-induced signaling in the absence of furin processing of Notch1. Dev. Biol. 2001, 229:494-502.
6. Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G., Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G., Dal Cin P., Dye J.M., Whelan S.P., Chandran K., Brummelkamp T.R. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011, 477:340-343.
7. Chaipan C., Kobasa D., Bertram S., Glowacka I., Steffen I., Tsegaye T.S., Takeda M., Bugge T.H., Kim S., Park Y., Marzi A., Pöhlmann S. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009, 83:3200-3211.
8. Chandran K., Sullivan N.J., Felbor U., Whelan S.P., Cunningham J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308:1643-1645.
9. Choi S.Y., Bertram S., Glowacka I., Park Y.W., Pöhlmann S. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol. Med. 2009, 15:303-312.
10. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944.
11. Cote M., Misasi J., Ren T., Bruchez A., Lee K., Filone C.M., Hensley L., Li Q., Ory D., Chandran K., Cunningham J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011, 477:344-348.
12. Feldmann H., Geisbert T.W. Ebola haemorrhagic fever. Lancet 2011, 377:849-862.
13. Geisbert T.W., Hensley L.E., Larsen T., Young H.A., Reed D.S., Geisbert J.B., Scott D.P., Kagan E., Jahrling P.B., Davis K.J. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 2003, 163:2347-2370.
14. Glowacka I., Bertram S., Herzog P., Pfefferle S., Steffen I., Muench M.O., Simmons G., Hofmann H., Kuri T., Weber F., Eichler J., Drosten C., Pöhlmann S. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 2010, 84:1198-1205.
15. Glowacka I., Bertram S., Muller M.A., Allen P., Soilleux E., Pfefferle S., Steffen I., Tsegaye T.S., He Y., Gnirss K., Niemeyer D., Schneider H., Drosten C., Pöhlmann S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 2011, 85:4122-4134.
16. Hallenberger S., Bosch V., Angliker H., Shaw E., Klenk H.D., Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992, 360:358-361.
17. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15:690-698.
18. Hartman A.L., Towner J.S., Nichol S.T. Ebola and Marburg hemorrhagic fever. Clin. Lab Med. 2010, 30:161-177.
19. Hofmann H., Hattermann K., Marzi A., Gramberg T., Geier M., Krumbiegel M., Kuate S., Uberla K., Niedrig M., Pöhlmann S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 2004, 78:6134-6142.
20. Hood C.L., Abraham J., Boyington J.C., Leung K., Kwong P.D., Nabel G.J. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J. Virol. 2010, 84:2972-2982.
21. Huang I.C., Bosch B.J., Li W., Farzan M., Rottier P.M., Choe H. SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry. Adv. Exp. Med. Biol. 2006, 581:335-338.
22. Kaletsky R.L., Simmons G., Bates P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J. Virol. 2007, 81:13378-13384.
23. Kühl A., Banning C., Marzi A., Votteler J., Steffen I., Bertram S., Glowacka I., Konrad A., Sturzl M., Guo J.T., Schubert U., Feldmann H., Behrens G., Schindler M., Pöhlmann S. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 2011, 204(Suppl 3):S850-S860.
24. Kühl A., Hoffmann M., Muller M.A., Munster V.J., Gnirss K., Kiene M., Tsegaye T.S., Behrens G., Herrler G., Feldmann H., Drosten C., Pöhlmann S. Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J. Infect. Dis. 2011, 204(Suppl 3):S840-S849.
25. Mahanty S., Hutchinson K., Agarwal S., McRae M., Rollin P.E., Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 2003, 170:2797-2801.
26. Martinez O., Johnson J., Manicassamy B., Rong L., Olinger G.G., Hensley L.E., Basler C.F. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell. Microbiol. 2010, 12:148-157.
27. Marzi A., Akhavan A., Simmons G., Gramberg T., Hofmann H., Bates P., Lingappa V.R., Pöhlmann S. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J. Virol. 2006, 80:6305-6317.
28. Matsuyama S., Nagata N., Shirato K., Kawase M., Takeda M., Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010, 84:12658-12664.
29. McCune J.M., Rabin L.B., Feinberg M.B., Lieberman M., Kosek K.J.C., Reyes G.R., Weissmann I.L. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988, 53:55-67.
30. Mehdi S. Cell-penetrating inhibitors of calpain. Trends Biochem. Sci. 1991, 16:150-153.
31. Neumann G., Feldmann H., Watanabe S., Lukashevich I., Kawaoka Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 2002, 76:406-410.
32. Neumann G., Geisbert T.W., Ebihara H., Geisbert J.B., Daddario-DiCaprio K.M., Feldmann H., Kawaoka Y. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J. Virol. 2007, 81:2995-2998.
33. O'Doherty U., Swiggard W.J., Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 2000, 74:10074-10080.
34. Sanchez A. Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity. J. Infect. Dis. 2007, 196(Suppl 2):S251-S258.
35. Schornberg K., Matsuyama S., Kabsch K., Delos S., Bouton A., White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 2006, 80:4174-4178.
36. Schornberg K.L., Shoemaker C.J., Dube D., Abshire M.Y., Delos S.E., Bouton A.H., White J.M. Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8003-8008.
37. Shah P.P., Wang T., Kaletsky R.L., Myers M.C., Purvis J.E., Jing H., Huryn D.M., Greenbaum D.C., Smith A.B., Bates P., Diamond S.L. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol. Pharmacol. 2010, 78:319-324.
38. Shirogane Y., Takeda M., Iwasaki M., Ishiguro N., Takeuchi H., Nakatsu Y., Tahara M., Kikuta H., Yanagi Y. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 2008, 82:8942-8946.
39. Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S., Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 2011, 85:873-882.
40. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11876-11881.
41. Takada A., Watanabe S., Ito H., Okazaki K., Kida H., Kawaoka Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 2000, 278:20-26.
42. Takada A., Fujioka K., Tsuiji M., Morikawa A., Higashi N., Ebihara H., Kobasa D., Feldmann H., Irimura T., Kawaoka Y. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 2004, 78:2943-2947.
43. Towner J.S., Sealy T.K., Khristova M.L., Albarino C.G., Conlan S., Reeder S.A., Quan P.L., Lipkin W.I., Downing R., Tappero J.W., Okware S., Lutwama J., Bakamutumaho B., Kayiwa J., Comer J.A., Rollin P.E., Ksiazek T.G., Nichol S.T. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS.Pathog 2008, 4:e1000212.
44. Volchkov V.E., Feldmann H., Volchkova V.A., Klenk H.D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5762-5767.
45. Wong A.C., Sandesara R.G., Mulherkar N., Whelan S.P., Chandran K. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J. Virol. 2010, 84:163-175.
46. Wool-Lewis R.J., Bates P. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J. Virol. 1999, 73:1419-1426.
47. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 2000, 6:886-889.
48. Yano H., Torkin R., Martin L.A., Chao M.V., Teng K.K. Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing. J. Neurosci. 2009, 29:14790-14802.
49. Yoshii H., Kamiyama H., Minematsu K., Goto K., Mizota T., Oishi K., Katunuma N., Yamamoto N., Kubo Y. Cathepsin L is required for ecotropic murine leukemia virus infection in NIH3T3 cells. Virology 2009, 394:227-234.